Crewe Advisors’s NovoCure NVCR Stock Holding History

Crewe Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-44	Closed	-$3K	–	1181
2022 Q3	$3K	Hold	44	–	–	﹤0.01%	971
2022 Q2	$3K	Buy	+44	New	+$3.31K	﹤0.01%	905

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crewe Advisors's NVCR Position: Q4 2022 in Review

Crewe Advisors sold out of NovoCure (NVCR) in Q4 2022, closing a stake of 44 shares — an estimated $3K sold.

Crewe Advisors first reported a position in NVCR in Q2 2022 and held it in 2 quarters. The position peaked at $3K in Q3 2022. 304 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

Crewe Advisors reported no remaining NovoCure position as of Q4 2022 after selling out during the quarter.
Crewe Advisors sold 44 NovoCure shares in Q4 2022, an estimated $3K.
Crewe Advisors first reported a position in NovoCure in Q2 2022 and held it in 2 quarters.
Crewe Advisors's NovoCure position peaked at $3K in Q3 2022.
304 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on Crewe Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.